ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC

Season 10, Episode 35, Jun 10, 07:40 PM

OncLive On Air partners with Two Onc Docs to bring insights on primary data from the LAURA trial, which were presented at the 2024 ASCO Annual Meeting.

Audioboom uses Javascript

Please enable it in your browser's preferences.

You can visit our support center if you're having problems.

Sorry, your browser isn't supported by Audioboom.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.

ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC

Subscribe

Next

Rosenberg Reviews the Evolving Role of Toripalimab in Nasopharyngeal Carcinoma

Top episodes

FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer

D'Abreo Addresses AEs in Metastatic Breast Cancer Care

Sorry, your browser isn't supported by Audioboom.

Page load failed